SCHEMBL21895625

SCHEMBL21895625

CCCN(C[C@@H](C)CC#N)c1nc(OC[C@@H](C)C[C@H](CC)OC)nc(CC)c1CCCCc1cccc2ccccc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21846313 0.88 — —
SCHEMBL25020089 0.75 — —
SCHEMBL21846275 0.74 — —
SCHEMBL21846280 0.72 — —
SCHEMBL21846184 0.71 — —
SCHEMBL21846435 0.71 — —
SCHEMBL21912059 0.70 — —
SCHEMBL21895733 0.70 — —
SCHEMBL25020009 0.69 — —
SCHEMBL21846318 0.68 ADRA2A (0.37) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020055756-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2020-03-19 — — WO disclosed
Send feedback